High uptake of RSVpreF vaccine and nirsevimab was observed, with 64% of pregnant individuals and 70% of infants receiving ...

A cohort study found that nearly three fourths of infants received respiratory syncytial virus protection with either nirsevimab or through exposure to maternal RSVpreF in the 2023-2024 season.

When existing systems do not accommodate access to health care innovation, we must change those systems. Fulfilling nirsevimab’s promise will require overcoming entrenched hospital payment norms.

USA: Researchers have found in a new study that a respiratory syncytial virus (RSV) prevention strategy combining prenatal ...

The medication – nirsevimab – is given via injection to infants under 8 months old. Unlike a vaccine, the immunization ...

The VDH reported on May 22 that a second juvenile in the "Under 10" age range has died of COVID-19 since the pandemic began ...

A study today in JAMA Network Open from the University of California, San Francisco (UCSF), shows a high uptake of respiratory syncytial virus (RSV) vaccine and the RSV-preventing monoclonal antibody ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

The medication, called nirsevimab, is given via injection to infants under eight months old and uses lab-made antibodies to ...